[{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fesoterodine","moa":"Muscarinic M2 receptor","graph1":"Urology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fesoterodine","moa":"Muscarinic M2 receptor","graph1":"Urology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Fesoterodine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Fesoterodine

                          Therapeutic Area : Urology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) Extended-Release Tablets, a muscarinic antagonist indicated for the treatment of overactive bladder.

                          Brand Name : Fesoterodine Fumarate-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 08, 2022

                          Lead Product(s) : Fesoterodine

                          Therapeutic Area : Urology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Dr Reddy Company Banner

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Alembic Fesoterodine Fumarate-Generic is therapeutically equivalent to Pfizer Fesoterodine Fumarate Extended-Release Tablets indicated for the treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and frequency.

                          Brand Name : Fesoterodine Fumarate-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 02, 2022

                          Lead Product(s) : Fesoterodine

                          Therapeutic Area : Urology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank